ASH 2020 Highlights

January 23, 2021

THIS IS A VIRTUAL ACTIVITY 


Description

The care of patients with hematologic malignancies is evolving rapidly. This virtual continuing medical education activity will discuss new developments in the diagnosis and treatment of hematologic malignancies, as presented at the 2020 Annual Meeting of the American Society of Hematology (ASH).

During this one-day virtual course, faculty will share the latest updates in lymphoma, leukemia, myeloma, and stem cell transplantation. Through case-based presentations and Q&A, attendees will gain a deeper understanding of emerging treatments available for blood cancers and blood disorders and learn how these new therapies can be integrated into daily practice.

Target Audience

This activity is directed toward hematologists, medical oncologists, internists, nurse practitioners, oncology nurses, and other interested healthcare providers.

Learning Objectives

At the conclusion of this course, attendees will be able to:

  1. Describe an overview and highlight the recent medical advances presented at the 2020 Annual Meeting of the American Society of Hematologists (ASH), which will help physicians achieve better patient outcomes.
  2. Recognize appropriate management and treatment options for hematologic malignancies and utilize these approaches in routine clinical practice.
  3. Recognize new therapies and approaches in non-malignant hematology.
     

About the Center for Hematologic Oncology at Dana-Farber/Brigham and Women's Cancer Center

We offer advanced, specialized care for patients with all types of hematologic malignancies, including leukemia and similar bone marrow disorders, lymphoma, multiple myeloma, Waldenström’s macroglobulinemia, and other related blood disorders.

Dana-Farber/Brigham and Women’s Cancer Center is at the forefront of stem cell transplantation, performing more than 500 transplants each year. Our team of specialists are national leaders in basic and clinical research designed to bring cutting-edge, innovative therapies to patients with blood cancers. The program is committed to working closely with referring oncologists to jointly devise clinical strategies to improve the care of our patients.


 

Additional Information

Provided by: 

Dana-Farber/Brigham and Women's Cancer Center and Mass General Brigham

 

Course summary
Available credit: 
  • 5.75 AMA PRA Category 1 Credit™
  • 5.75 Participation
Course opens: 
01/06/2021
Course expires: 
02/25/2021
Event starts: 
01/23/2021 - 7:00am
Event ends: 
01/23/2021 - 2:30pm
Cost:
$50.00
If you would like to choose a breakout room to attend in advance, please email your preference to Kaitlin_Stratton@DFCI.HARVARD.EDU. Space will be limited. Clinicians only please.

 
Dana-Farber Cancer Institute
Boston, MA
United States

Ann S. LaCasce, MD, MMSc - Course Director
Director, Dana-Farber/Mass General Brigham Hematology-Medical Oncology Fellowship Program,
Medical Oncologist, Adult Lymphoma Program,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine, Harvard Medical School

Nathan T. Connell, MD, MPH
Clinical Chief of Hematology, Brigham and Women’s Faulkner Hospital;
Hematologist, Adult Hematology Treatment Center,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine, Harvard Medical School

Matthew S. Davids, MD, MMSc
Director, Clinical Research, Lymphoma Program,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine, Harvard Medical School

Daniel J. DeAngelo, MD, PhD
Chief, Division of Leukemia,
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Medicine, Harvard Medical School

Mahasweta Gooptu, MD
Medical Oncologist, Stem Cell Transplantation Program,
Dana-Farber/Brigham and Women’s Cancer Center;
Instructor in Medicine, Harvard Medical School

Eric D. Jacobsen, MD
Clinical Director, Adult Lymphoma Program,
Director, Histiocyte Disorders Center,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine, Harvard Medical School

Jacob Laubach, MD, MPP
Clinical Director, Jerome Lipper Multiple Myeloma Center,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine, Harvard Medical School

Richard M. Stone, MD
Chief of Staff, Dana-Farber Cancer Institute;
Director, Translational Research, Adult Leukemia Program,
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Medicine, Harvard Medical School

Mass General Brigham is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Mass General Brigham designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

Available Credit

  • 5.75 AMA PRA Category 1 Credit™
  • 5.75 Participation

Price

Cost:
$50.00
Please login or register to take this course.